Gene targeting in ischemic heart disease and failure: Translational and clinical studies
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 85 (1) , 1-11
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health (HL057952, HL059165, HL095608)
- National Institute of Health (T32 HL007260)
This publication has 92 references indexed in Scilit:
- GRK2 as a novel gene therapy target in heart failureJournal of Molecular and Cellular Cardiology, 2011
- S100A1: A Multifaceted Therapeutic Target in Cardiovascular DiseaseJournal of Cardiovascular Translational Research, 2010
- piggyBac Transposon-mediated Long-term Gene Expression in MiceMolecular Therapy, 2010
- A Transposon and Transposase System for Human ApplicationMolecular Therapy, 2010
- VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN TrialMolecular Therapy, 2009
- Transposon-mediated genome manipulation in vertebratesNature Methods, 2009
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- Applying a “Double-Feature” Promoter to Identify Cardiomyocytes Differentiated from Human Embryonic Stem Cells Following Transposon-Based Gene DeliveryStem Cells, 2009
- Recombinant Adeno-associated Virus Transduction and IntegrationMolecular Therapy, 2008
- New Signaling Pathways Associated With Increased Cardiac Adenylyl Cyclase 6 Expression: Implications for Possible Congestive Heart Failure TherapyTrends in Cardiovascular Medicine, 2007